Onco-Innovations Raises C$5 Million to Accelerate ONC010 Cancer Program

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced a non-brokered private placement of 6,764,069 units at C$0.7392 per unit, for gross proceeds of approximately C$5 million. Each unit consists of one common share and one warrant exercisable at C$0.90 per share for three years. The financing is expected to close on or about July 10, 2026, subject to regulatory approvals, including approval from Cboe Canada.

Proceeds from the offering will be directed toward advancing the company's ONC010 program through manufacturing and preclinical testing activities. Additionally, funds will support development of the SynoGraph platform and provide working capital for general corporate purposes. The offering is conducted under Canada's Listed Issuer Financing Exemption, and securities issued will not be subject to a hold period under applicable Canadian securities laws.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumours.

This financing marks a critical step for Onco-Innovations as it moves ONC010 toward clinical readiness. The ONC010 program is based on proprietary technology aimed at addressing unmet needs in solid tumour treatment. By securing funding for manufacturing and preclinical testing, the company can advance its pipeline and potentially bring new therapeutic options to patients.

For full details, the press release is available at https://www.nnw.fm/QatCe. The latest news and updates regarding ONNVF can be accessed at the company's newsroom at https://nnw.fm/ONNVF.